# MRG003

Source: https://onco.cc/drugs/mrg003/  
OnCo record `mrg003` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MRG003 is an experimental antibody-drug conjugate from Lepu Biopharma in phase 3 trials for head and neck squamous cell carcinoma and nasopharyngeal carcinoma, with its target not yet stated publicly.

## Summary

MRG003 is an antibody-drug conjugate developed by Lepu Biopharma. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05751512 (A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN), in head and neck squamous cell carcinoma and nasopharyngeal carcinoma. The largest, NCT05126719, plans to enrol 238 participants with primary completion was scheduled for 2024-12-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of MRG003: https://clinicaltrials.gov/search?intr=MRG003
- Sponsor page: https://www.lepubiopharma.com

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)](https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Recurrent and metastatic nasopharyngeal carcinoma](https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/), [Recurrent or metastatic head and neck squamous cell carcinoma](https://onco.cc/cancers/recurrent-metastatic-hnscc/)
- companies: [Lepu Biopharma](https://onco.cc/companies/lepu-biopharma/)
- trials: [A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin](https://onco.cc/trials/nct06976190/), [A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN](https://onco.cc/trials/nct05751512/), [A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma](https://onco.cc/trials/nct05126719/)

---
JSON: https://onco.cc/api/v1/entities/mrg003.json